There are a number of reasons why enrollment in the Affordable Care Act's health insurance plans is lower than initially estimated, according to a new report.
In assessing the marketplace enrollment of the Affordable Care Act (ACA), researchers examine why rates are lower than those originally predicted by the Congressional Budget Office (CBO) and establish what may be a more accurate vision of growth in the future.
At the end of the third open enrollment period under the ACA, 12.7 million individuals had signed up for coverage from health insurance marketplaces, and this number is presumed to settle to just over 10 million by the end of 2016. Although similar to projections from HHS, this estimate falls short of the projections from CBO, which has nearly halved its estimates from 21 million to 13 million.
The authors have several hypotheses as to why enrollment is lower than originally calculated. Firstly, CBO thought that employer coverage would decline so that employees would be allowed to take advantage of certain subsidies. As this decline has not manifested, it’s possible that the ACA incentives for employers to maintain benefits is greater than first supposed.
Secondly, many adults continue to buy insurance outside of the marketplace, including ACA-compliant plans, “grandfathered” plans, and “transitional” plans. This number is expected to drop, however. Thirdly, many consider affordability a challenge. The team speculated if this is a result of lack of awareness of financial help.
In order to more precisely predict the future rate of enrollment, the researchers suggest looking at the experiences of top-performing states. If all states improved to at least the average of the top 10 states, 16.3 million would sign up with an ending estimate of 14.7 million. This appears to be a more reasonable ceiling for the next couple of years.
Enrollment growth is important for a variety of reasons: to fulfill the ACA’s goal of less uninsured adults, to stabilize premiums by creating a healthier pool of applicants, and to attract more insurers, which is central for a successful marketplace.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More